September deal: save 5% when you pay onlineBook here or call +971 (0) 4379 3562
Smartcare Polyclinic Logo

Weight & Metabolic

What Happens When You Stop a GLP-1?

The trials that made these medicines famous also followed what happened after people stopped. That part rarely makes the headlines.

Most conversations about GLP-1 medicines stop at the weight loss figure. The more useful question — and the one that decides whether the whole exercise was worth it — is what happens a year after the last injection.

There is published evidence on exactly this, and it is worth understanding before starting rather than after.

The withdrawal data

The STEP 1 trial extension followed participants for a year after treatment and lifestyle intervention were withdrawn. Participants regained roughly two-thirds of the weight they had lost. Mean weight loss had been 17.3% at week 68; by week 120, a year after stopping, the net loss from baseline was 5.6%.

The cardiometabolic improvements followed the same pattern — blood pressure, lipids and glycaemic markers largely returned toward where they started.

The authors' conclusion is the important sentence: the findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain the improvement.

Why the body pushes back

Weight is defended. When body fat falls, appetite-regulating hormones shift in a direction that increases hunger and reduces energy expenditure, and those changes persist well beyond the period of weight loss itself. A GLP-1 works against that pressure while it is being taken; removing it removes the counterweight, not the pressure.

This is the same reason weight regained after a restrictive diet is so common, and it is a physiological finding rather than a comment on anyone's willpower.

What a maintenance plan actually involves

There is no single correct answer, and anyone offering one is overreaching. The realistic options discussed in practice include continuing at a maintenance dose, tapering slowly with close monitoring, or planning a structured handover to nutrition, resistance training and regular review.

What all of them have in common is that they are decided in advance, with a doctor, and reviewed as you go — not improvised when a prescription runs out.

  • Agree the target rate of loss and the review schedule before starting
  • Build the nutrition and activity changes during treatment, not after it
  • Protect muscle mass — resistance training matters more than most people expect
  • Know what stopping will look like, and what support exists when you do

The questions to ask before you start

A good consultation should be able to answer all of these. If a clinic cannot, that in itself is informative.

  • What is driving my weight, and have we investigated it?
  • What is the plan if I do not respond, or cannot tolerate the medicine?
  • How often will I be reviewed, and what will be monitored?
  • What is the plan for stopping, and what happens to my weight then?

Common questions

Will I regain all the weight if I stop?

The published extension data showed participants regained about two-thirds of the weight lost in the year after withdrawal, leaving a net loss from baseline. That is an average across a trial population; individual outcomes vary, and what you do after stopping matters.

Can I take a GLP-1 short term to lose weight quickly?

The evidence does not support treating these medicines as a short course. Obesity behaves as a chronic condition in the trials, and the improvements largely reverse when treatment stops. That is a conversation to have with your doctor before starting, not after.

Does exercise change what happens after stopping?

Maintaining muscle mass and activity is part of every credible maintenance plan, and there is reasonable evidence it helps. It is not a guarantee against regain, and it works best when built during treatment rather than started afterwards.

References

  1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022;24(8):1553-1564.
  2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002.

This article is general health information, not medical advice, and does not replace a consultation. Care at Smart Care Polyclinic is provided by DHA-licensed clinicians.

Related at Smart Care

More on weight & metabolic

Ozempic, Wegovy, Mounjaro: What the Evidence Actually ShowsConfused by GLP-1 weight loss medicines? A doctor-written guide to what semaglutide and tirzepatide are, what the published trials found, and who they are for.